Biophytis and LynxKite Expand AI-Driven Drug Discovery for Longevity Therapies

Partnership aims to accelerate development of next-generation treatments for sarcopenia and age-related macular degeneration

Mar. 13, 2026 at 6:03pm

Got story updates? Submit your updates here. ›

Biophytis SA and LynxKite Technologies have expanded their partnership to leverage AI and computational methods for drug discovery targeting age-related diseases. The collaboration will focus on developing new treatments for sarcopenia, a degenerative muscle disease, and dry age-related macular degeneration. LynxKite will integrate its AI and analytics capabilities into Biophytis' longevity research platform, with the goal of rapidly identifying and testing promising drug candidates.

Why it matters

As the global population ages, there is a growing need for innovative therapies to address debilitating age-related conditions like sarcopenia and macular degeneration. This partnership combines Biophytis' expertise in longevity research with LynxKite's advanced AI and computational tools, aiming to accelerate the discovery and development of next-generation treatments that could significantly improve quality of life for the elderly.

The details

The initial MASSIVE project will focus on identifying and developing Mas receptor (MasR) activator drug candidates to target sarcopenia. Biophytis will contribute its experience in age-related diseases and MasR pharmacology, while LynxKite will leverage its AI technologies, chemoinformatics, and scalable GPU computing to model the MasR structure, design and prioritize synthetic drug candidates, and validate the most promising compounds through in vitro and in vivo testing.

  • The partnership expansion was announced on March 13, 2026.

The players

Biophytis SA

A clinical-stage biotechnology company focused on developing drug candidates for age-related diseases, including sarcopenia and metabolic disorders.

LynxKite Technologies

A leader in advanced analytics and artificial intelligence, known for its flagship open-source platform LynxKite, which supports data analysis and AI model development for global enterprises.

Nebius

An AI cloud company building a platform for developers and companies to deploy AI products, agents, and services.

Stanislas Veillet

CEO of Biophytis.

Gyorgy Lajtai

CEO of LynxKite.

Got photos? Submit your photos here. ›

What they’re saying

“The launch of MASSIVE marks a decisive step in our longevity strategy, combining our clinical expertise with LynxKite's innovative AI to accelerate the discovery of transformative therapies against sarcopenia.”

— Stanislas Veillet, CEO of Biophytis (PRNewswire)

“We are proud to collaborate with Biophytis on pioneering computational longevity through our LynxKite platform, which demonstrates how LynxKite can revolutionize discovery by designing, integrating and orchestrating relevant computational tools in diverse modalities.”

— Gyorgy Lajtai, CEO of LynxKite (PRNewswire)

What’s next

The partners plan to expand the computational longevity platform to develop next-generation drug candidates for additional age-related conditions, such as dry age-related macular degeneration.

The takeaway

This strategic alliance between Biophytis and LynxKite showcases how the integration of domain expertise and advanced AI capabilities can accelerate the discovery of innovative therapies to address the growing challenge of age-related diseases and support healthy longevity.